Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice

Eriko Kusaka, Mayu Sugiyama, Norie Senoo, Atsuki Yamamoto, Yukio Sugimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glucocorticoids (GCs) are well known for their anti-inflammatory effects, which are elicited through a transcriptional mechanism via a cytosolic glucocorticoid receptor (cGR)-mediated genomic effect. However, recent in vitro studies report that GCs can act as a membrane glucocorticoid receptor (mGR). This study aimed to examine whether mometasone furoate (MF) influences the nasal symptoms induced by histamine, substance P, ATP. Furthermore, the influences of various compounds on MF action were studied in vivo. The mice were intranasally administered with nasal symptom-inciting agents, and the occurrences of sneezing and nasal rubbing were counted. MF repressed the nasal symptoms caused when it was administered 10, 30 and 60 min before the induction of nasal symptoms. The repressive effect observed 10 min after the administration of MF was inhibited by RU486, a GR antagonist, but not by actinomycin D, a transcriptional inhibitor. In contrast, the repressive effect observed 60 min after the administration of MF was inhibited by RU486 and actinomycin D. Therefore, the effects observed 10 and 60 min after the MF administration were classified as non-genomic and genomic effects, respectively. The non-genomic effect suppressed the nasal symptoms induced by m-3M3FBS, a phospholipase C (PLC) activator, and was inhibited by U-73122, a PLC inhibitor. The genomic effect was inhibited by N-(p-amylcinnamoyl) anthranilic acid, a phospholipase A2 (PLA2) inhibitor. These results indicate that MF has a non-genomic effect through repression of the activation of PLC via the mGR, and MF has also a genomic effect that was influenced by the inhibition of PLA 2 through transcriptional regulation via cGR.

Original languageEnglish
Pages (from-to)279-287
Number of pages9
JournalInternational Immunopharmacology
Volume16
Issue number2
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Mometasone Furoate
Glucocorticoids
Nose
Glucocorticoid Receptors
Type C Phospholipases
Dactinomycin
Sneezing
Membranes
Allergic Rhinitis
Substance P

Keywords

  • Genomic effect
  • Glucocorticoid Mometasone furoate
  • Nasal rubbing
  • Non-genomic effect
  • Sneezing

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice. / Kusaka, Eriko; Sugiyama, Mayu; Senoo, Norie; Yamamoto, Atsuki; Sugimoto, Yukio.

In: International Immunopharmacology, Vol. 16, No. 2, 06.2013, p. 279-287.

Research output: Contribution to journalArticle

Kusaka, Eriko ; Sugiyama, Mayu ; Senoo, Norie ; Yamamoto, Atsuki ; Sugimoto, Yukio. / Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice. In: International Immunopharmacology. 2013 ; Vol. 16, No. 2. pp. 279-287.
@article{d8ceee9087294312806158cacc3d0027,
title = "Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice",
abstract = "Glucocorticoids (GCs) are well known for their anti-inflammatory effects, which are elicited through a transcriptional mechanism via a cytosolic glucocorticoid receptor (cGR)-mediated genomic effect. However, recent in vitro studies report that GCs can act as a membrane glucocorticoid receptor (mGR). This study aimed to examine whether mometasone furoate (MF) influences the nasal symptoms induced by histamine, substance P, ATP. Furthermore, the influences of various compounds on MF action were studied in vivo. The mice were intranasally administered with nasal symptom-inciting agents, and the occurrences of sneezing and nasal rubbing were counted. MF repressed the nasal symptoms caused when it was administered 10, 30 and 60 min before the induction of nasal symptoms. The repressive effect observed 10 min after the administration of MF was inhibited by RU486, a GR antagonist, but not by actinomycin D, a transcriptional inhibitor. In contrast, the repressive effect observed 60 min after the administration of MF was inhibited by RU486 and actinomycin D. Therefore, the effects observed 10 and 60 min after the MF administration were classified as non-genomic and genomic effects, respectively. The non-genomic effect suppressed the nasal symptoms induced by m-3M3FBS, a phospholipase C (PLC) activator, and was inhibited by U-73122, a PLC inhibitor. The genomic effect was inhibited by N-(p-amylcinnamoyl) anthranilic acid, a phospholipase A2 (PLA2) inhibitor. These results indicate that MF has a non-genomic effect through repression of the activation of PLC via the mGR, and MF has also a genomic effect that was influenced by the inhibition of PLA 2 through transcriptional regulation via cGR.",
keywords = "Genomic effect, Glucocorticoid Mometasone furoate, Nasal rubbing, Non-genomic effect, Sneezing",
author = "Eriko Kusaka and Mayu Sugiyama and Norie Senoo and Atsuki Yamamoto and Yukio Sugimoto",
year = "2013",
month = "6",
doi = "10.1016/j.intimp.2013.03.030",
language = "English",
volume = "16",
pages = "279--287",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Genomic and non-genomic effects of glucocorticoids on allergic rhinitis model in mice

AU - Kusaka, Eriko

AU - Sugiyama, Mayu

AU - Senoo, Norie

AU - Yamamoto, Atsuki

AU - Sugimoto, Yukio

PY - 2013/6

Y1 - 2013/6

N2 - Glucocorticoids (GCs) are well known for their anti-inflammatory effects, which are elicited through a transcriptional mechanism via a cytosolic glucocorticoid receptor (cGR)-mediated genomic effect. However, recent in vitro studies report that GCs can act as a membrane glucocorticoid receptor (mGR). This study aimed to examine whether mometasone furoate (MF) influences the nasal symptoms induced by histamine, substance P, ATP. Furthermore, the influences of various compounds on MF action were studied in vivo. The mice were intranasally administered with nasal symptom-inciting agents, and the occurrences of sneezing and nasal rubbing were counted. MF repressed the nasal symptoms caused when it was administered 10, 30 and 60 min before the induction of nasal symptoms. The repressive effect observed 10 min after the administration of MF was inhibited by RU486, a GR antagonist, but not by actinomycin D, a transcriptional inhibitor. In contrast, the repressive effect observed 60 min after the administration of MF was inhibited by RU486 and actinomycin D. Therefore, the effects observed 10 and 60 min after the MF administration were classified as non-genomic and genomic effects, respectively. The non-genomic effect suppressed the nasal symptoms induced by m-3M3FBS, a phospholipase C (PLC) activator, and was inhibited by U-73122, a PLC inhibitor. The genomic effect was inhibited by N-(p-amylcinnamoyl) anthranilic acid, a phospholipase A2 (PLA2) inhibitor. These results indicate that MF has a non-genomic effect through repression of the activation of PLC via the mGR, and MF has also a genomic effect that was influenced by the inhibition of PLA 2 through transcriptional regulation via cGR.

AB - Glucocorticoids (GCs) are well known for their anti-inflammatory effects, which are elicited through a transcriptional mechanism via a cytosolic glucocorticoid receptor (cGR)-mediated genomic effect. However, recent in vitro studies report that GCs can act as a membrane glucocorticoid receptor (mGR). This study aimed to examine whether mometasone furoate (MF) influences the nasal symptoms induced by histamine, substance P, ATP. Furthermore, the influences of various compounds on MF action were studied in vivo. The mice were intranasally administered with nasal symptom-inciting agents, and the occurrences of sneezing and nasal rubbing were counted. MF repressed the nasal symptoms caused when it was administered 10, 30 and 60 min before the induction of nasal symptoms. The repressive effect observed 10 min after the administration of MF was inhibited by RU486, a GR antagonist, but not by actinomycin D, a transcriptional inhibitor. In contrast, the repressive effect observed 60 min after the administration of MF was inhibited by RU486 and actinomycin D. Therefore, the effects observed 10 and 60 min after the MF administration were classified as non-genomic and genomic effects, respectively. The non-genomic effect suppressed the nasal symptoms induced by m-3M3FBS, a phospholipase C (PLC) activator, and was inhibited by U-73122, a PLC inhibitor. The genomic effect was inhibited by N-(p-amylcinnamoyl) anthranilic acid, a phospholipase A2 (PLA2) inhibitor. These results indicate that MF has a non-genomic effect through repression of the activation of PLC via the mGR, and MF has also a genomic effect that was influenced by the inhibition of PLA 2 through transcriptional regulation via cGR.

KW - Genomic effect

KW - Glucocorticoid Mometasone furoate

KW - Nasal rubbing

KW - Non-genomic effect

KW - Sneezing

UR - http://www.scopus.com/inward/record.url?scp=84877802231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877802231&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2013.03.030

DO - 10.1016/j.intimp.2013.03.030

M3 - Article

C2 - 23583558

AN - SCOPUS:84877802231

VL - 16

SP - 279

EP - 287

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -